Assays for more specific amyloid and tau proteins are providing a more precise window on AD biology, and neurofilament light chain (NfL) appears to provide a sensitive marker of axonal injury across multiple neurological conditions. The gene discussed is MAPT; the disease is Alzheimer disease.